Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging

Zaider, Marco; Zeléfsky, Michael J.; Lee, Eva K.; Zakian, Kristen L.; Amols, Howard; Dyke, Jonathan P.; Cohen, Gilad; Hu, Yu-Chi; Endi, Alev K; Chui, Chen‐Shou; Koutcher, Jason A.

doi:10.1016/s0360-3016(00)00557-5

Cited by 130 publications

(81 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hirose et al noticed that the volume and superoinferior height of the prostate gland do not change in a consistent fashion (39). Zaider et al have shown that the total volume of the prostate remains constant during compressed and uncompressed state (41). They also reported that points within the gland maintain the same relative position with respect to the axial contours of the prostate, and have no displacement in the superior-inferior direction.…”

Section: Discussionmentioning

confidence: 96%

“…Most literature reports discuss the distortion of prostate when the endorectal balloon is inflated with 100 cm 3 air (41,42), with the maximum distortion reported to be of the order of 4 mm. In the majority of the cases studied by us only 50-60 cm 3 air was used to inflate the balloon and hence the distortion expected may be less than that reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional ¹H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml

et al. 2006

View full text Add to dashboard Cite

Results of the evaluation of transrectal ultrasound (TRUS) guided needle biopsy of voxels identified as suspicious of malignancy on magnetic resonance spectroscopic imaging (MRSI) in a large cohort of men (n = 83) with abnormal digital rectal examination (DRE) [prostate specific antigen (PSA) 0-4 ng/ml] or PSA less than 10 ng/ml, are reported. Three-dimensional (1)H MRSI was carried out at 1.5 T using a pelvic-phased array coil in combination with an endorectal surface coil. Voxels were classified as suspicious of malignancy based on Cit/(Cho + Cr) metabolite ratio. TRUS-guided biopsy of suspicious voxels was performed using the z- and x-coordinates obtained from MR images and two to three cores were taken from the suspected site. A systematic sextant biopsy was also carried out. MRSI showed voxels suspicious of malignancy in 44 patients while biopsy revealed cancer in 11 patients (25%). Patients who were negative for malignancy on MRSI were also negative on biopsy. An overall sensitivity of 100%, specificity of 54%, negative predictive value of 100% and accuracy of 60% were obtained. The site of biopsy was confirmed (n = 20) as a hypo-intense area on repeat MRI while repeat MRSI revealed high choline and low citrate. The overall success rate of MRI-directed TRUS-guided biopsy of 25% was higher compared with a 9% success rate achieved without MR guidance in another group of 120 patients. Our results indicate that TRUS-guided biopsy of suspicious area identified as malignant from MRSI can be performed using the coordinates of the voxel derived from MR images. This increases the detection rate of prostate cancer in men with PSA level <10 ng/ml or abnormal DRE and also demonstrates the potential of MR in routine clinical practice.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional ¹H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml

et al. 2006

View full text Add to dashboard Cite

show abstract

“…MRI, MRSI, and biopsy results can also be used to define the distribution of dominant intraprostatic lesions (DILs) within the prostate (79). Two recent studies indicated the potential of MRI/MRSI data in combination with CT to optimize radiation dose selectively to regions of prostate cancer using either intensity modulated radiotherapy (IMRT) (92) or brachytherapy (93).…”

Section: Future Directionsmentioning

confidence: 99%

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

Kurhanewicz

Swanson

Nelson

et al. 2002

Magnetic Resonance Imaging

331

266

View full text Add to dashboard Cite

Magnetic resonance spectroscopic imaging (MRSI) provides a noninvasive method of detecting small molecular markers (historically the metabolites choline and citrate) within the cytosol and extracellular spaces of the prostate, and is performed in conjunction with high-resolution anatomic imaging. Recent studies in pre-prostatectomy patients have indicated that the metabolic information provided by MRSI combined with the anatomical information provided by MRI can significantly improve the assessment of cancer location and extent within the prostate, extracapsular spread, and cancer aggressiveness. Additionally, pre-and post-therapy studies have demonstrated the potential of MRI/MRSI to provide a direct measure of the presence and spatial extent of prostate cancer after therapy, a measure of the time course of response, and information concerning the mechanism of therapeutic response. In addition to detecting metabolic biomarkers of disease behavior and therapeutic response, MRI/MRSI guidance can improve tissue selection for ex vivo analysis. High-resolution magic angle spinning ( 1 H HR-MAS) spectroscopy provides a full chemical analysis of MRI/MRSI-targeted tissues prior to pathologic and immunohistochemical analyses of the same tissue. Preliminary 1 H HR-MAS spectroscopy studies have already identified unique spectral patterns for healthy glandular and stromal tissues and prostate cancer, determined the composition of the composite in vivo choline peak, and identified the polyamine spermine as a new metabolic marker of prostate cancer. The addition of imaging sequences that provide other functional information within the same exam (dynamic contrast uptake imaging and diffusion-weighted imaging) have also demonstrated the potential to further increase the accuracy of prostate cancer detection and characterization.

show abstract

“…Data exists from other biological imaging methods, namely MRS. Choline and citrate metabolism within cytosol and the extracellular space of the prostate were investigated. Clinical trials analyzing cancer location and extent within the prostate, extracapsular spread and cancer aggressiveness in pre-prostatectomy patients have indicated that the metabolic information provided by MRS combined with the anatomic information provided by MRI can significantly improve the diagnosis [16,84,92,144,148]. The integration of H-MRS in brachytherapy treatment planning of patients with organ-confined but aggressive prostatic cancer could improve the tumor control probability.…”

Section: Acetate Pet In the Diagnosis Of Prostate Cancermentioning

confidence: 99%

Positron Emission Tomography for Radiation Treatment Planning

et al. 2005

View full text Add to dashboard Cite

show abstract

Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging

Cited by 130 publications

References 44 publications

Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional ¹H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml

Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional ¹H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

Positron Emission Tomography for Radiation Treatment Planning

Contact Info

Product

Resources

About

Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging

Cited by 130 publications

References 44 publications

Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional 1H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml

Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional 1H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml

Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

Positron Emission Tomography for Radiation Treatment Planning

Contact Info

Product

Resources

About

Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional ¹H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml

Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional ¹H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml